Distribution of Legionella species and serogroups in patients with culture-confirmed Legionella pneumonia
- PMID: 32081644
- DOI: 10.1016/j.jiac.2019.12.016
Distribution of Legionella species and serogroups in patients with culture-confirmed Legionella pneumonia
Abstract
Legionella species are consistently identified as some of the most common causative agents of severe community-acquired pneumonia (CAP) or nosocomial pneumonia. Although the number of reported Legionella infection cases is gradually increasing in Japan, most cases are diagnosed by a urinary antigen test, which identifies only L. pneumophila serogroup 1. Therefore, assessment of pneumonia-causing Legionella species and serogroups would be important. The Japan Society for Chemotherapy Legionella committee has collected the isolates and clinical information on cases of sporadic community-acquired Legionella pneumonia throughout Japan. Between December 2006 and March 2019, totally 140 sporadic cases were identified, in which L. pneumophila was the most frequently isolated species (90.7%) followed by L. bozemanae (3.6%), L. dumofii (3.6%), L. micdadei (1.4%), and L. longbeachae (0.7%). Among 127 isolates of L. pneumophila, 111 isolates were of serogroup 1, two of serogroup 2, four of serogroup 3, one of serogroup 4, one of serogroup 5, seven of serogroup 6, and one was of serogroup 10. We also assessed in vitro activity of antibiotics against these isolates and showed that quinolones and macrolides have potent anti-Legionella activity. Our study showed that pneumonia-causing Legionella species and serogroup distribution was comparable to that reported in former surveillances. L. pneumophila was the most common etiologic agent in patients with community-acquired Legionella pneumonia, and L. pneumophila serogroup 1 was the predominant serogroup.
Keywords: Community-acquired pneumonia; Legionella pneumophila; Minimum inhibitory concentration (MIC); Serogroups; Species.
Copyright © 2020 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest Naoyuki Miyashita has received speaker honoraria from Daiichi Sankyo Co., Ltd., Astellas Pharma Inc., Pfizer Japan Inc., and Taisho Toyama Pharmaceutical Co., Ltd. Yosuke Aoki has received speaker honoraria from MSD K.K., Shionogi & Co., Ltd. and Pfizer Japan Inc.; and grant support from Shionogi & Co., Ltd. Toshiaki Kikuchi has received grant support from Chugai Pharmaceutical Co., Ltd., Boehringer Ingelheim Japan, Inc., Daiichi Sankyo Co., Ltd., Ono Pharmaceutical Co., Ltd., and Astellas Pharma Inc. Masafumi Seki has received speaker honoraria from MSD K.K., Pfizer Japan Inc., Taisho Toyama Pharmaceutical Co., Ltd., and Shionogi & Co., Ltd. Kazuhiro Tateda has received speaker honoraria from Pfizer Japan Inc., MSD K.K., Sumitomo Dainippon Pharma Co., Ltd., Meiji Seika Pharma Co., Ltd. and Taisho Toyama Pharmaceutical Co., Ltd.; research funding from Otsuka Pharmaceutical Co., Ltd., grant support from Astellas Pharma Inc., Daiichi Sankyo Co., Ltd., Pfizer Japan Inc., Taiho Pharmaceutical Co., Ltd., Taisho Toyama Pharmaceutical Co., Ltd., Japan Blood Products Organization, Asahi Kasei Pharma Corporation, Sumitomo Dainippon Pharma Co., Ltd., Shionogi & Co., Ltd., Meiji Seika Pharma Co., Ltd., and Toyama Pharmaceutical Co., Ltd.; and donations from Kyorin Pharmaceutical Co., Ltd., GlaxoSmithKline K.K., Astellas Pharma Inc., Meiji Seika Pharma Co., Ltd., Daiichi Sankyo Co., Ltd., Taisho Toyama Pharmaceutical Co., Ltd., and MSD K.K. Nobuko Maki is an employee of Taisho Toyama Pharmaceutical Co., Ltd. Kazuhiko Uchino is an employee of Daiichi Sankyo Co., Ltd. Hiroshi Kiyota has received grant support from Taisho Toyama Pharmaceutical Co., Ltd., Toyama Chemical Co., Ltd., Daiichi Sankyo Co., Ltd., Astellas Pharma Inc., and Taiho Pharmaceutical Co., Ltd. Akira Watanabe has received speaker honoraria from MSD K.K., Kobayashi Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., Daiichi Sankyo Co., Ltd., Taisho Toyama Pharmaceutical Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Mitsubishi Tanabe Pharma Co., Chugai Pharmaceutical Co., Ltd., Pfizer Japan Inc., UCB Japan Co. Ltd., AbbVie GK and GlaxoSmithKline K.K.; donations from Astellas Pharma Inc., Daiichi Sankyo Co., Ltd., and Sumitomo Dainippon Pharma Co., Ltd.; payments for manuscript drafting and editing from Iyaku (Medicine and Drug) Journal Co., Ltd.; and grant support from Kyorin Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., Daiichi Sankyo Co., Ltd., Taisho Toyama Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd., Toyama Chemical Co., Ltd., Fujifilm Pharma Co., Ltd., and Meiji Seika Pharma Co., Ltd.
Similar articles
-
Severe community-acquired pneumonia due to Legionella pneumophila Serogroup 6.J Formos Med Assoc. 2006 Mar;105(3):256-62. doi: 10.1016/S0929-6646(09)60316-8. J Formos Med Assoc. 2006. PMID: 16520845
-
Distribution of Legionella species and serogroups isolated by culture in patients with sporadic community-acquired legionellosis: an international collaborative survey.J Infect Dis. 2002 Jul 1;186(1):127-8. doi: 10.1086/341087. Epub 2002 May 21. J Infect Dis. 2002. PMID: 12089674
-
Legionella species infection in adult febrile respiratory tract infections in the community.Scand J Infect Dis. 2002;34(1):1-4. doi: 10.1080/00365540110076831. Scand J Infect Dis. 2002. PMID: 11874157
-
[Community-acquired pneumonia due to Legionella pneumophila serogroup 1. Study of 97 cases].Enferm Infecc Microbiol Clin. 2003 Oct;21(8):394-400. Enferm Infecc Microbiol Clin. 2003. PMID: 14525703 Review. Spanish.
-
Legionella spp.: community acquired and nosocomial infections.Curr Opin Infect Dis. 2003 Apr;16(2):145-51. doi: 10.1097/00001432-200304000-00011. Curr Opin Infect Dis. 2003. PMID: 12734447 Review.
Cited by
-
The Impact of Storms on Legionella pneumophila in Cooling Tower Water, Implications for Human Health.Front Microbiol. 2020 Dec 10;11:543589. doi: 10.3389/fmicb.2020.543589. eCollection 2020. Front Microbiol. 2020. PMID: 33362725 Free PMC article.
-
Sensitivity of Legionella pneumophila to phthalates and their substitutes.Sci Rep. 2023 Dec 13;13(1):22145. doi: 10.1038/s41598-023-49426-1. Sci Rep. 2023. PMID: 38092873 Free PMC article.
-
Legionella pneumophila Subspecies fraseri Infection after Allogeneic Hematopoietic Stem Cell Transplant, China.Emerg Infect Dis. 2022 Apr;28(4):903-905. doi: 10.3201/eid2804.211433. Emerg Infect Dis. 2022. PMID: 35318935 Free PMC article.
-
A case of severe pneumonia caused by Legionella longbeachae with positive results by a Legionella urinary antigen detection kit.Ther Adv Infect Dis. 2023 Jun 14;10:20499361231179863. doi: 10.1177/20499361231179863. eCollection 2023 Jan-Dec. Ther Adv Infect Dis. 2023. PMID: 37363443 Free PMC article.
-
Thermodynamic Study on Biomimetic Legionella gormanii Bacterial Membranes.Molecules. 2024 Sep 14;29(18):4367. doi: 10.3390/molecules29184367. Molecules. 2024. PMID: 39339363 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous